[Studies on renal dysfunction after intra-arterial hypertensive chemotherapy (CDDP, PEP) for advanced cancer of the uterine cervix--serum.urinary alpha 1-microglobulin, beta 2-microglobulin and urinary lysozyme, albumin].
The present study evaluated the degree of renal impairment caused by intra-arterial hypertensive chemotherapy (CDDP, PEP). In 11 cases of advanced cancer of the uterine cervix, serum and urinary levels of alpha 1-microglobulin (alpha 1-m) and beta 2-microglobulin (beta 2-m), and urinary albumin (Alb) and lysozyme (LZM) were determined before the chemotherapy and 1,2 and 3 weeks after the therapy. Results are summarized as follows: 1. After intra-arterial chemotherapy, the histological classification was Grade I in 1 case (9.1%), Grade IIa in 2 cases (18.2%), and Grade IIb in 8 cases (72.7%). 2. Serum alpha 1-m and beta 2-m levels remained within the normal range after chemotherapy. 3. Urinary alpha 1-m, beta 2-m and LZM levels exceeded the normal limit between 1 and 2 weeks after the therapy, but thereafter they returned to normal. 4. Urinary Alb was significantly increased (p less than 0.05) between 1 and 2 weeks after therapy, but thereafter it returned to normal. These results suggested that intra-arterial chemotherapy (CDDP 100mg and PEP 40 mg in a dose) was effective for advanced cancer of the cervix and that renal disorders including tubular and glomerular impairment, which are the adverse effects of the therapy, were mild and reversible.
Department of Obstetrics and Gynecology, Shimane Medical University.
O
O
Iwanari
Y
Y
Date
N
N
Yoshino
J
J
Miyako
K
K
Ryuhkoh
M
M
Moriyama
S
S
Nakayama
M
M
Kitao
D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000139:chemically induced* / Q000652:urine; D000510:Alpha-Globulins / Q000378:metabolism* / Q000652:urine; D000804:Angiotensin II / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D001794:Blood Pressure / Q000187:drug effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D006801:Humans; D007261:Infusions, Intra-Arterial; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008875:Middle Aged; D009113:Muramidase / Q000652:urine*; D017663:Peplomycin; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D001613:beta 2-Microglobulin / Q000378:metabolism* / Q000652:urine
D000510:Alpha-Globulins; C016001:alpha-1-microglobulin; D001613:beta 2-Microglobulin; D001761:Bleomycin; D000804:Angiotensin II; D017663:Peplomycin; D009113:Muramidase; D002945:Cisplatin